Cite
HARVARD Citation
Miksad, R. et al. (n.d.). O-022Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Annals of oncology. p. . [Online].